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Congenital hypogonadotrophic hypogonadism (CHH) is a rare but important etiology of
pubertal failure and infertility, resulting from impaired gonadotrophin-releasing hormone
secretion or action. Despite the availability of effective hormonal therapies, the majority
of men with CHH experience unsatisfactory outcomes, including chronic psychosocial
and reproductive sequelae. Early detection and timely interventions are crucial to address
the gaps in medical care and improve the outlook for these patients. In this paper, we
review the clinical implications of missing minipuberty in CHH and therapeutic strategies
that can modify the course of disease, as well as explore a targeted approach to
identifying affected male infants by integrating clinical and biochemical data in the early
postnatal months.
Keywords: congenital hypogonadotropic hypogonadism, kallmann syndrome, puberty delay, minipuberty of
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INTRODUCTION
Congenital hypogonadotrophic hypogonadism (CHH) is a rare genetic condition characterized by
reproductive disorder due to deficiency in secretion or action of gonadotrophin-releasing hormone
(GnRH). It is traditionally considered to be a male-predominant condition, with a male: female
gender ratio 3.6: 1 that remains unexplained (1). The major clinical consequences of CHH are
pubertal failure and infertility.
Although generally considered a rare disorder, accurate determination of the prevalence of
CHH has not been possible because of scarce literature. Based on a French study of potential
military conscripts who attendedmedical examination (2) and, more recently, a retrospective study
of nationwide hospital records in Finland (3), (both of which were methodologically prone to
under-ascertainment), male CHH prevalence of 1 in 4,415–15,000 is currently estimated.
The genetic defects underpinning CHH broadly fall into two principle groups, comprising
(a) those causing neurodevelopmental defects of GnRH neuron migration frequently associated
with non-reproductive defects, particularly anosmia/hyposmia from olfactory axon misrouting
(i.e., Kallmann syndrome–KS), and (b) those causing pure neuroendocrine impairment of GnRH
secretion or action (normosmic CHH). Belying this apparently simple dichotomy is the huge
diversity of genetic mutations, with over 30 gene loci implicated to date, despite nearly half of
CHH cases remaining unaccounted for. Moreover, some genes are implicated in both normosmic
CHH and KS (4). This complexity is also reflected in the various modes of transmission possible,
including oligogenicity as well as all forms of classical Mendelian inheritance (4, 5).
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Furthermore, CHH is phenotypically heterogeneous. Besides
the variable association with non-reproductive features, such
as deafness, synkinesis (mirror movements), renal agenesis,
digital and dental anomalies, and clefting, reproductive
manifestation range from absent puberty, pubertal arrest, to
even spontaneous reversal of hypogonadism in a small minority
(5). CHH males frequently present with cryptorchidism and/or
micropenis, which are important features of severe fetal-infancy
GnRH deficiency (absent minipuberty) (6). However, patient
experiences indicate that these early presentations only rarely
signpost timely disease recognition and treatment-initiation in
later life.
Despite medical advances in genetics, diagnostics and
treatment, health outcomes of CHH men remain disappointing,
with a significant proportion bearing the long-term consequences
of suboptimal care (7). In this chapter, we will review the
factors contributing to poor outcomes of men with CHH, and
the strategies that can improve the quality of life and fertility
potential, with special focus on harnessing the window of
minipuberty for early diagnosis, and intervention.
DELAYED DIAGNOSIS AND TREATMENT
Delayed puberty is the mainmode of presentation in CHHmales.
Approximately 2/3 of CHH males adolescents do not show any
sign of spontaneous puberty at >17 years of age (testis volume
<4mL), with the remainder exhibiting arrested early puberty (8).
Unfortunately, CHH is biochemically indistinguishable from
constitutional delay in growth and puberty (CDGP), the latter
accounting for up to 65% of delayed puberty in younger teenage
boys (9), but obviously declining precipitously with advancing
age at presentation. Both conditions are characterized by low
sex steroids in association with low or inappropriately normal
follicle-stimulating hormone (FSH) and luteinizing hormone
(LH) levels. In terms of their height development, the baseline
height SD scores and growth velocities do not appear to differ
significantly between CDGP and CHH adolescents, unlike in
functional hypogonadotrophic hypogonadism where there is a
tendency for lower height SD scores and reduced growth velocity
of<3 cm/year (9, 10). It is however worth noting that progressive
reduction in height SDs has been observed in a proportion of
CDGP boys during the pre-pubertal years, with final attained
height falling short of their genetic potential (11). On the other
hand, preservation of height relative to parental height in CHH
patients has been suggested (12). Hence, careful interrogation of
the growth history can yield useful information.
Although a variety of stimulation tests (such as GnRH
stimulation test and hCG test) and, recently, inhibin B (IB)
concentrations (marker of Sertoli cell function), have been
proposed, there is still lack of consensus on the “gold standard”
test to reliably distinguish them (13). Hence, making a diagnosis
of CHH remains a challenging task and clinicians frequently
default to the classic dogma of expectant management, i.e.,
allowing adolescents enough time for those with CDGP to
undergo spontaneous initiation of puberty, as a means to identify
those with CHH (14). It is noteworthy that in a recent large single
center retrospective series, the combination of testicular volume
and basal IB level–both of which are obtainable with relative
ease without the involvement of complicated dynamic tests–
demonstrated utility in discriminating between CHH and CDGP,
and therefore could have the potential for wider application(10).
However, there seems to be consistent misapplication of
“wait & see & reassure” guidance (intended for individuals with
undifferentiated pubertal delay) to those with red flag markers
of CHH who should, instead, be presumed hypogonadal until
proven otherwise and receive sex hormone replacement from
mean age of pubertal-onset in that population i.e., 12 years in
boys (6, 15), whereas treatment should not be unduly withheld
in those without CHH features but have turned 14 years old (16).
As a result, the diagnosis of CHH and initiation of clinically-
meaningful treatment to induce puberty is typically unduly
delayed until late adolescence or early adulthood. Despite
different survey techniques across different European countries,
data on the mean ages of diagnosis and initiation of clinically-
meaningful1 treatment for CHH men have been remarkably
consistent, with Dwyer et al (web-based, pan-European; n= 101)
finding these to be 18 ± 6 and 19 ± 5 years, respectively (7);
Raivio et al (nationwide Finnish cohort study) finding themedian
age of starting treatment to be 18.3 years (range, 11–34 years)
(17), and Quinton (case notes based survey; n = 200) finding it
to be 18.9± 9 years (18).
A surprisingly common pitfall is the failure to recognize the
significance of cryptorchidism in an adolescent with pubertal
delay. In retrospective CHH series, between 30 and 50% of
CHH males have a history of cryptorchidism, of whom up to
2/3 have bilateral undescended testes (8, 19–21). By contrast,
cryptorchidism is very rare in CDGP. In a large series of boys
seen at a specialized center referred from primary care for delayed
puberty, only 2% of CDGP boys had a history of cryptorchidism,
compared with 36% of those with CHH (10). Hence, a history of
cryptorchidism should alert clinicians to presume the diagnosis
of CHH until proven otherwise (22). A concomitant family
history of cryptorchidism, micropenis, infertility and/or non-
reproductive features such as anosmia, renal agenesis and cleft
palate/lip could provide valuable clues to an underlying diagnosis
of CHH, though it is absent in majority of cases, in part due to
variable disease penetrance and phenotypic expression, as well as
oligogenic inheritance with unaffected parents (4).
Likewise, the significance of bilateral undescended testes
in neonates as a possible indicator of CHH is typically
underappreciated. Persistent bilateral cryptorchidism is found
in a quarter of CHH infants, as compared to <0.7% among
infants in the general population (Table 1) In a large single-
center retrospective series, only one-third of CHH males with
history of bilateral orchidopexy in childhood were referred
to pediatric endocrinology for evaluation, with most cases
re-presenting much later in life with absent puberty (19).
Current clinical guidelines have largely focused on evaluation
for possible congenital adrenal hyperplasia (CAH) and disorder
1For instance, 50mg intramuscular testosterone monthly would not remotely
constitute appropriate or meaningful replacement therapy for a 20 year-old, 1.7m
and 70kg prepubertal male with Kallmann syndrome.
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TABLE 1 | “Red Flag” clinical markers for congenital GnRH deficiency*.
INDICATORS OF ABSENT MALE MINIPUBERTY
All apparent at or shortly after birth
- Cryptorchidism (38% compared with general population prevalence
3.68–6.9% at birth, 1.0–2.4% at 3 months) (23–26)
- Bilateral cryptorchidism (25% compared with general population
1.66–4.54% at birth, 0.09–0.66% at 3–12 months) (23–26)
- Microphallus (9% compared with general population birth prevalence
0.015–0.35%) (27, 28)
- Absent erections on nappy change
NON-REPRODUCTIVE PHENOTYPES STRONGLY ASSOCIATED
WITH CHH
Apparent at or shortly after birth
- Cleft lip and/or palate (5% compared with general population prevalence
0.1%) (29–31)
- Hearing impairment via automated optoacoustic emissions test (6%
compared with UK birth prevalence 0.12%) (32)
Usually apparent by 6–8 years of age
- Anosmia or hyposmia [43% compared with general population prevalence
1.4–19.1% (comprising both congenital & acquired)] (33–35)
FAMILY HISTORY OF CHH
Including offspring of CHH patients from ovulation- or spermatogenesis-
induction (risk apparent even preconception)
*Composite data including 4 published studies (8, 19–21).
of sex development (DSD), and neglected to provide sufficient
guidance on the investigations necessary in cryptorchid boys
to rule out CHH (36, 37), resulting in missed opportunity for
early recognition.
As a result of late diagnosis and delayed treatment, the optimal
standard of care is not delivered with patients with CHH, leading
to significant psychosocial and reproductive sequelae.
UNMET HEALTH NEEDS
Poor Psychological Well-Being
Psychological morbidities and antidepressant usage are highly
prevalent among CHH men (17). In an international study
comprising of participants from North and South America,
Europe and Australasia, nearly two-thirds suffered from
depression, with majority of them exhibiting moderate to severe
symptoms (38). An important consequence arising from chronic
affective disorders is poor adherence to long-term hormone
replacement. It is concerning that more than one-third of the
survey respondents reported long gaps (>1 year) in treatment,
which could potentially exacerbate affective symptoms in turn as
part of a vicious cycle.
The psychosexual impact of the disease is tremendous. A
significant number of patients suffer from anxiety and low
self-esteem, resulting in inability to form intimate relationships
and social isolation. Consequently, in the aforementioned study
cohort (38), approximately 50% of the men were not in a
stable relationship at the time of survey, and many never had a
sexual partner.
On the positive side, the majority of men surveyed had
received tertiary level education and were in gainful employment,
reflecting reasonable socioeconomic circumstances, although
this did not negate the psychological effects of their disorder.
However, CHH men with adopted or biological children were
less likely to report depressive symptoms, suggesting the positive
effect of family companionship, and the vicious circle that
socially-withdrawn CHHmen may be trapped in.
A major factor that contributes to poor mental health and
impaired quality of life is the delay in diagnosis and the
failure to administer age-appropriate induction of secondary
sexual characteristic in many CHH males. As alluded to earlier,
most patients only start to receive meaningful treatment in
late adolescence (median age 18–19 years) typically after a
prolonged and frustrating diagnostic odyssey (frequently shared
by their female counterparts too) (1). Consequently, they are
at risk of developing a multitude of psychosocial problems
associated with pubertal delay, including low self-esteem, social
withdrawal, poor school performance and even higher rates of
substance use disorder (16, 39, 40). Furthermore, inadequately
treated cryptorchidism and/or micropenis can lead to long-
lasting adverse impact on their sexuality (17).
Compromised Fertility Potential
In young adult males with CHH, gonadotrophin treatment
achieves a significantly greater positive impact than direct
testosterone (T) replacement on health-related quality of life
(41). While both treatments are effective in improving physical
function and general health, patients receiving gonadotrophins
perform better in psychological domains, including emotional
and mental health, particularly if sperms are found in ejaculate.
This strongly suggests that patients psyches are deeply affected by
their perceived chances of achieving paternity.
The infertility in CHH patients is due to spermatogenic
failure, which is potentially amenable to GnRH or gonadotrophin
treatment. Unfortunately, classic spermatogenic treatment–
human chorionic gonadotrophin (hCG) monotherapy or
combined gonadotropin treatment (hCG+FSH)–is much less
successful in men with severe CHH (testes <4mL), particularly
those with history of bilateral cryptorchidism, than in men
with HH of postpubertal-onset, e.g., due to acquired pituitary
disease (42). Nonetheless, in centers experienced in the care of
CHH patients, up to three-quarters can achieve spermatogenesis
during hormonal induction treatment (6, 43), and pregnancy
rates can be further enhanced with assisted reproductive
techniques (6, 44).
Patients with rare medical disorders, defined by a prevalence
of <5 in 10,000 in the population, often face challenges due
to the lack of knowledge of their healthcare providers (45,
46). As such, specialized centers with expertise in diagnosis
and interdisciplinary treatment of rare diseases are vital in
the provision of care to these patients (47). Similarly, patients
with CHH should ideally receive tertiary-level care to avoid
gaps in treatment, and benefit from the latest technologies and
advances in the research field. Early diagnosis would provide the
opportunity for patients to receive appropriate and consistent
care and support at specialized centers without delay. Treatment
can also be tailored according to the needs and goals in different
stages of life (6, 48).
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But in real-life setting, according to one survey, it appears
that only a minority of CHH men seeking fertility are able to
achieve desired outcomes on fertility-inducing treatment (7). It is
unclear how many of these men were treated at centers with the
necessary expertise, but given that only half of the whole study
cohort being followed-up at specialized/academic centers, access
to such resources is likely to be correspondingly restricted.
Elevated Risk for Low Bone Mineral
Density
Chronic sex steroid deficiency is a major risk factor for
osteoporosis and fragility fractures that affects both genders. As
men with CHH have early-onset of T insufficiency, a delay in
and/or lack of adequate androgen replacement would result in
poor bone mass accretion and accelerated bone loss (49). Indeed,
patients who are initiated on T replacement at older age appear
to accrue less bone mineral compared to younger age, further
supporting the importance of timely treatment (50). Nonetheless,
even for those who are diagnosed and started on treatment
only later in life, encouraging improvement in bone mineral
density, particularly at trabecular-rich lumber spine, has been
observed (51).
MINIPUBERTY–CRITICAL PERIOD OF
GENITALIA DEVELOPMENT AND THE
WINDOW TO EARLY DIAGNOSIS
High incidence of cryptorchidism and microphallus is observed
in CHH males because of the absence of minipuberty, which
is a critical period in the ontogenesis of the male reproductive
tract, characterized by activation of the GnRH axis in the
initial months postnatal. During this developmental phase, serum
T and gonadotropin levels rise rapidly and peak at age 3
months–remarkably approaching adult male levels–before to
mid-childhood quiescence by about 6 months of age (52, 53).
This robust hormonal activity is necessary to complete the
processes of inguinoscrotal testicular descent and anchoring in
the scrotum as well as penile growth, which had begun earlier
in utero during the third trimester. Specifically, LH-stimulated
secretion of T and INSL3 peptide by Leydig cells are the key
factors involved in driving these physical changes (54, 55).
There is a concurrent exponential increase in FSH-stimulated
IB and anti-Müllerian hormone (AMH) secretion, signifying
active proliferation of Sertoli cells. Expansion of Sertoli and germ
cells and seminiferous tubule formation are key determinants of
future fertility potential and are responsible for 90% of testicular
volume (56). Despite the brisk gonadotrophic activity and T
secretion during this proliferative phase, germ cell maturation
and spermatogenesis do not occur, because androgen receptors
are not expressed on Sertoli cells until 5 years of age (57).
Following minipuberty, the hypothalamic-pituitary-testicular
(HPT) axis retreats into quiescence for the rest of childhood.
Serum T, LH, and FSH levels decline to low levels until
reactivation of gonadal axis occurs in early adolescence, heralding
the onset of puberty and marked by testicular enlargement
(≥4mL), followed by penile and pubic hair growth. At this stage,
Sertoli cell maturation occurs, evidenced by a rise in IB and
decline in AMH levels, and spermatogenesis is achieved by the
concerted actions of FSH and intra-testicular T (58). Therefore,
pulsatile GnRH secretion in the neonatal period appears to be
paramount for the normal development of male genitalia, with a
far-reaching impact on male reproductive phenotype and fertility
potential later in adult life.
Another important clinical implication of minipuberty is
that it potentially provides a window-of-opportunity to facilitate
detection of children with congenital GnRH deficiency, who
would demonstrate abnormally low FSH, LH, and T levels
if measured, thereby offering the advantage of a definitive
prepubertal diagnosis and sign-posting them to pre-planned
pubertal-induction with sex hormones at median age of pubertal-
onset, rather than expectative management.
Early Diagnosis for Avoiding Delay in
Pubertal Induction
Diagnosis of CHH in early life facilitates the structuring of long-
term surveillance and treatment plans, as well as ensuring that
counseling and psychological support to patients and families
are made available. When patients reach early adolescence,
age-appropriate pubertal induction treatment will ensure that
secondary sexual characteristics develop in tandem with peers
(15), thereby avoiding the delay that has been traditionally
experienced by most CHH men. As such, uncertainties are
minimized and anxieties can be allayed.
Potential Benefit of Early Diagnosis in
Improving Prospect of Fertility
Early identification of boys with CHH could also plausibly
provide the opportunity for intervention to optimize
fertility potential. Although GnRH or gonadotrophin
combination treatment are effective for most CHH men in
spermatogenesis-induction, sperm outcomes are generally
suboptimal (43, 59, 60). Moreover, nearly one-third with severe
CHH remain azoospermic even with prolonged combined
gonadotropin therapy, and hCG-monotherapy has proved to be
despairingly ineffective.
Clinical features (consistent with long-standing severe
GnRH deficiency minipuberty) that are predictive of poor
treatment response, include: complete absence of puberty
at presentation, cryptorchidism (especially if bilateral), low
serum IB concentrations (indicating depleted Sertoli cells)
and prepubertal testicular volume (indicating depletion of
Sertoli and germ cells and seminiferous tubules) (43, 59).
On the other hand, CHH men with partial GnRH deficiency
(testicular volume ≥4mL) respond much better to combined
gonadotrophin treatment, with around 80% achieving sperm in
the ejaculate (61).
Therefore, in men with complete CHH, it would be
theoretically advantageous to first maximize proliferation of
Sertoli and germ cell and growth of seminiferous tubules by
administering FSH-monotherapy prior to the introduction of
hCG, so as to prevent premature maturation of a depleted pool
of Sertoli cells under the influence of intra-testicular T.
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Pathfinder studies of FSH-monotherapy in children and
adolescents with HH of prepubertal-onset demonstrated its
efficacy in promoting testicular growth and circulating IB
concentrations (62, 63). In particular, there was an encouraging
spermatogenesis response in a subgroup of CHH adolescents,
in whom FSH-priming before the combination with hCG
successfully induced spermatogenesis in 3 out of 4 patients (63).
The potential benefit of unopposed FSH treatment was further
studied in a randomized, open-label trial of 13 treatment-naive
adult CHH men with prepubertal testes (<4mL) (64). Seven
men were randomized to recombinant FSH-pretreatment for
4 months before embarking on a 24-month GnRH treatment
protocol. During the FSH-only phase, testicular volume doubled
and IB levels rose to adult levels, and all subjects in this arm
subsequently developed sperm in ejaculate on GnRH therapy,
compared to 4 of 6 men in the 24-month GnRH-only arm. There
were also trends to larger testicular volume, higher maximal
sperm counts and shorter time to first appearance of sperm in
the ejaculate in the FSH-pretreated group.
Therefore, the findings of the benefits of FSH-priming and
the potential deleterious effect of premature hCG therapy would
be important to inform clinicians on the choice of treatment
in adolescents with CHH, which would be greatly facilitated by
timely diagnosis.
Potential of Neonatal Gonadotrophin
Treatment to Further Optimize Outcomes
Recognizing the critical role of minipuberty in the development
of external genitalia and Sertoli cell proliferation and its
subsequent influence on future reproductive function, the
feasibility and benefits of recreating the physiological hormonal
milieu in male CHH infants has been studied.
In the first published report of a boy with CHH and
micropenis who received short-term recombinant human LH
and FSH from age 7.9–13.7 months, the penile length successfully
increased by 50% and the testicular volume nearly tripled by the
end of treatment (65). In another report of 2 male infants, one
case each of combined pituitary hormone deficiency (CPHD)
and CHH, 6-month gonadotrophin combination therapy via
subcutaneous pump infusion initiated at age 8 and 20 weeks,
respectively, led to 4-fold increase in both penile length and
testicular volume (66). More recently, 3–6 months of continuous
subcutaneous infusion of recombinant human gonadotrophins
in 5 male infants [4 CHH, 1 CPHD] produced several-
fold increase in IB concentrations, testicular volume, and T
secretion (67).
Besides these encouraging responses to combined
gonadotrophin treatment during infancy, it could also aid
in the management of undescended testes. Cryptorchidism is
present in approximately one-half of boys with severe CHH
(19), and it is an independent predictor of infertility. Delay
in orchidopexy has been associated with dramatic decline in
germ cells (68), and as such it is generally recommended that
surgical treatment take place by about 1 year of age (37, 69).
However, small testes render surgical manipulation technically
challenging and would result in excess risk of testicular trauma
and tissue loss (70). By administering a period of presurgical
gonadotrophin therapy, it allows the enlargement of testicular
volume to facilitate the procedure.
Indeed, there are emerging evidence that spontaneous
testicular descent could be successfully induced by
gonadotrophin treatment in infants with central hypogonadism,
and thus obviate the need for surgery. In a cohort of eight infants
with maldescended testes due to underlying hypogonadotrophic
hypogonadism (5 CHH, 3 CPHD), gonadotrophin infusion
induced full testicular descent in 6 boys and partial descent in
2 boys, such that only 1 had to undergo orchidopexy nearly
a year later because of re-ascent of both testes (71). Another
study showed that combined recombinant FSH and LH in
the first 6 months of life successfully induced spontaneous
testicular descent in 2 of 4 bilateral-cryptorchid CHH/CPHD
boys (67).
Therefore, short-term neonatal gonadotrophin treatment in
ascertained cases of hypogonadotrophic hypogonadism appears
to be effective in replicating the effects of minipuberty, by
correcting micropenis, promoting testicular growth due to
Sertoli cell expansion, and inducing spontaneous descent of
malpositioned testes. Importantly, treatment was well-tolerated
in all reported cases. Although definitive evidence is currently
lacking, the prospect of early childhood hormonal intervention
in CHH boys in augmenting sexual and reproductive function
in adult life is worth serious consideration, and hopefully will
provide impetus for larger clinical trials.
A PROPOSED STRATEGY TO IMPROVE
DETECTION OF MALE INFANTS WITH
SEVERE CHH
The phase of male minipuberty provides an extraordinary
useful diagnostic window to confirm (or refute) the diagnosis of
congenital hypogonadism with a relatively straightforward
biochemical hormone profiling without the need for
complex dynamic testing. In a cohort of CPHD male infants
(predominantly presenting with hypoglycaemia), findings of low
circulating FSH, LH, and T concentrations reliably identified
concomitant hypogonadotrophic hypogonadism in 14 of 15
infants with genitalia anomalies, whereas all other boys with
normal genitalia demonstrated intact pituitary-gonadal axis
function (72). This contrasts starkly with the conundrum of
differentiating CHH from CDGP in adolescence.
However, unlike CPHD, neonates with CHH without
cryptorchidism do not necessarily have clinical manifestations
that would trigger referral to pediatric endocrinologists for
pituitary hormonal evaluation. In addition, there is a lack
of awareness and clinical guidance to consider CHH as a
differential diagnosis of male infants with cryptorchidism,
particularly if bilateral or associated with micropenis, so that
appropriate evaluation can be undertaken (22, 37, 69). Indeed,
the presence of “red flag” markers (Table 1) should warrant
further investigations to exclude such a possibility.
Another challenge would be the interpretation of less robust
serum gonadotrophin and testosterone results in the male
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infants. Of relevance, normative data of several important
reproductive hormone values during minipuberty–including
LH, FSH, T (by both radioimmunoassay and tandem mass
spectrometry), AMH and IB-have recently been derived
from a large cohort of healthy Danish infants, with cut-off
values discriminating between sexes determined (53). By
extension, values above the cut-off levels–generally lower
than adult ranges–could be regarded as intactness of HPT
axis function, whereas equivocal biochemical results that
lie below the cut-off values may warrant repeat testing.
Furthermore, expanding screening panel to include AMH
and IB could improve diagnostic confidence. Crucially, this
study also demonstrated that the various sex hormones peak
just before 3.5 months of age, suggesting that diagnostic
performance would be most optimal when evaluation is
undertaken around this time.
Bilateral Cryptorchidism as Potential
Screening Criterion
While routine screening for minipuberty is impractical, a
targeted approach to evaluate male infants with suspicious signs
of CHH could be cost-effective. Among the associated clinical
features, bilateral cryptorchidism is particularly important
because of its high prevalence (13.9–34.5%) among CHH males
and the association with severe GnRH deficiency that has both
prognostic and therapeutic implications (8, 19, 21).
Although cryptorchidism is a common congenital urogenital
abnormality in newborns, most would undergo spontaneous
descent in the absence of hypogonadism or other organic
disorders. Data from prospective studies shows that the
prevalence of bilateral cryptorchidism decreases substantially
from 1.66 to 4.54% at time of birth to 0.09–0.66% by 3–12months
of age (23–26). In addition, spontaneous descent is unlikely
to occur beyond 3 months postnatal (73), which coincides
closely with the expected peak of minipuberty, making it an
ideal time point to undertake testing of reproductive hormones
in boys with persistent bilateral cryptorchidism. Moreover,
although non-CHH cryptorchid boys may also exhibit hormonal
abnormalities, they tend to have higher FSH, similar T and
slightly lower IB values compared to healthy infants, which are
different from the biochemical pattern expected of in CHH male
infants (74).
Therefore, testing male infants with bilateral cryptorchidism
with or without micropenis at 3 months of age for absent
minipuberty could potentially be a feasible approach to facilitate
the early diagnosis of CHH. The diagnostic yield of such a
selective screening strategy is explored here, using Britain’s birth
data as an example for mathematical illustration:
• With an average male live birth rate of 390,070 per annum in
Britain (75), between 26 and 88 boys born each year could
be affected by CHH (based on estimated prevalence of 1 in
4,415–15,000).
• On the other hand, bilateral cryptorchidism could affect
between 6,475 and 17,709 (1.66–4.54%) of all boys at birth,
regardless of the presence of CHH. Among them, between
4 and 30 infants could have underlying CHH (as bilateral
cryptorchidism affects 13.9–34.5% of CHH population), thus
representing 0.02–0.46% of all bilateral-cryptorchid boys
at birth.
• By 3 months of age, following spontaneous testicular descent
expected in majority of non-CHH infants, the total number
of infants with persistent bilateral cryptorchidism would be
expected to reduce substantially to between 351 and 2,574
(0.09–0.66%).
• As spontaneous testicular descent is not expected in CHH-
affected infants, they now account for greater proportion
of all persistently bilateral-cryptorchid boys: 0.16–8.55% (in
contrast to 0.02–0.46% at birth). Hence, screening at 3
months of age appears to be most cost-effective by avoiding
investigations in vast majority of infants without persistent
bilateral cryptorchidism.
Based on this hypothesis, possibly up to 1 in 11–12 male infants
with persistent bilateral cryptorchidism at 3 months of age could
have underlying CHH. Interestingly, this estimate is consistent
with the findings from an historical surgical series of patients
who had been treated with orchidopexy. In this study, of the
98 patients evaluated for possible underlying endocrine cause of
cryptorchidism, 2 were found to have CHH in adult life and both
of them had bilateral undescended testes (76). That represents
6.1% (2/33) of all individuals with bilateral cryptorchidism in
the series.
However, it is worth reiterating that, at present, there
is no literature to suggest that CHH screening in infancy
has been systematically studied by any research group, and
thus is a working concept that remains in early exploratory
phase. Further long-term multicentre research is necessary to
validate the utility of any screening strategy that seeks to
establish early diagnosis of this rare condition, as well as the
effectiveness and safety of hormonal treatment in CHH infants.
Protocols should also be developed collaboratively by pediatric
and adult endocrinologists to ensure that these children are
placed in a structured follow-up and transition programme,
thereby ensuring that no one falls through the crack in the
health system.
A Short Note on Pre-pubertal Acquired
Hypogonadotrophic Hypogonadism
Pubertal failure in male adolescents with known history
of acquired hypopituitarism generally avoids the diagnostic
conundrum of CHH, hence allowing pubertal-induction therapy
to be planned for at around 12 years of age, with gradual
increase in testosterone dose before reaching adult replacement
dose in about 3 years (15). Importantly, because of preserved
minipuberty, normal Sertoli cell proliferation is expected in
early childhood, and testicular maldescent would be less likely
to occur (63). Therefore, these individuals tend to have a
more optimistic fertility outlook, with greater spermatogenic
response to gonadotrophin treatment anticipated (77), unless
testicular tissue has been compromised e.g., prior gonadotoxic
chemotherapy treatment.
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CONCLUSION
Early detection of CHH through detection of absent minipuberty
can potentially modify patients’ experience by facilitating timely
interventions at different stages of life. This is achievable with a
systematic approach in place to identify male infants with “red
flag” markers of CHH, particularly bilateral cryptorchidism, so
that biochemical testing can be undertaken within the narrow
diagnostic window.
Neonatal gonadotrophin treatment appears to be beneficial in
correcting micropenis and even cryptorchidism. In adolescents,
age-appropriate pubertal induction is the main goal, and a brief
course of FSH monotherapy should be considered to optimize
future fertility potential. Close collaborations between pediatric
care providers and adult endocrinologists would ensure that these
patients transit smoothly to adulthood, during which the aims
of treatment would shift to fertility-induction and long-term
androgen replacement. Equally important are the psychological
support and genetic counseling that should be provided along the
way to empower patients, and families, so that they can cope with
their conditions confidently.
FUTURE DIRECTIONS
Proactive screening of male infants with bilateral cryptorchidism
(and/or micropenis) is anticipated to have a direct impact on
the quality of care delivered to affected children by establishing
early diagnosis. However, this issue has not been addressed
by major clinical guidelines developed for the management
of infants with abnormal genitalia, thereby leading to missed
opportunities for patients and clinicians alike in accessing
the most appropriate treatment possible. To overcome this
barrier, it is imperative that collaborative research by key
stakeholder centers seek to clarify the feasibility of such an
approach systematically, as well as expanding the work on
neonatal gonadotrophin treatment, so as to advance the agenda
for wider adoption among endocrinologists, pediatricians, and
pediatric surgeons.
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